Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons

Details for Australian Patent Application No. 2005251462 (hide)

Owner Novartis AG

Inventors Lambert, Olivier

Agent Davies Collison Cave

Pub. Number AU-B-2005251462

PCT Pub. Number WO2005/120453

Priority 0412866.6 09.06.04 GB

Filing date 8 June 2005

Wipo publication date 22 December 2005

Acceptance publication date 9 July 2009

International Classifications

A61K 9/00 (2006.01) Medicinal preparations characterised by special physical form

A61K 38/10 (2006.01) Medicinal preparations containing peptides - Peptides having 12 to 20 amino acids

A61K 47/10 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Alcohols

A61K 47/34 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds

Event Publications

4 January 2007 PCT application entered the National Phase

  PCT publication WO2005/120453 Priority application(s): WO2005/120453

9 July 2009 Application Accepted

  Published as AU-B-2005251462

5 November 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005251463-Anti-cancer composition comprising proline or its derivatives and an antitumour antibody

2005251461-1-`(3r)-amino-4-(2-fluoro-phenyl)-butyl !-pyrrolidine-(2r)-carboxilic acid-benzyl amine derivatives and related compounds as dipeptidyl-peptidase IV (DPP-IV) inhibitors for the treatment of Type 2 diabetes mellitus